



Agile Therapeutics  
Investor Relations Department  
101 Poor Farm Road  
Princeton, NJ 08540  
United States

Visit IR website [↗](#)  
Sign-up for email alerts [↗](#)

**NASDAQ: AGRX**


Last Trade:	3.84
Trade Time:	4:00 PM ET Jun 23, 2017
Change:	-0.07 <span style="color:red">▼</span> (-1.790%)
Day Range	3.83 - 4.05
52-Week Range	1.82 - 8.15
Volume	1,454,044

Stock information is provided by eSignal, stock charts provided by EDGAR Online. Stock data is delayed approximately 20 minutes.

## Company Profile

Agile Therapeutics is a forward-thinking women's healthcare company dedicated to fulfilling the unmet health needs of today's women. Our product candidates are designed to provide women with contraceptive options that offer freedom from taking a daily pill, without committing to a longer-acting method. Our lead product candidate, Twirla®, (ethinyl estradiol and levonorgestrel transdermal system), also known as AG200-15, is a once-weekly prescription contraceptive patch that recently completed Phase 3 trials. Twirla is based on our proprietary transdermal patch technology, called Skinfusion®, which is designed to provide advantages over currently available patches and is intended to optimize patch adhesion and patient wearability.

## Stock Performance



### Press Releases [\[ View all \]](#)

- May 8, 2017*  
[Agile Therapeutics Reports First Quarter 2017 Financial Results](#)
- May 6, 2017*  
[Agile Therapeutics Reports Additional Phase 3 SECURE Study Results Relating to Twirla® at ACOG 2017](#)
- May 3, 2017*  
[Agile Therapeutics to Present Additional Phase 3 Data at the 2017 Annual Clinical and Scientific Meeting of the American Congress of Obstetricians and Gynecologists](#)
- Apr 27, 2017*  
[Agile Therapeutics Announces Presentation of SECURE Phase 3 Data at the 2017 Congress on Women's Health](#)
- Apr 11, 2017*  
[Agile Therapeutics Announces Results of its Pre-Submission Meeting with FDA](#)

### Financials [\[ View all \]](#)

- Mar 15, 2017*  
[Annual Report \(10-K\)](#)
- Apr 24, 2017*  
[Proxy Statement \(DEF 14A\)](#)
- May 8, 2017*  
[Quarterly Report \(10-Q\)](#)
- Nov 7, 2016*  
[Quarterly Report \(10-Q\)](#)
- Aug 8, 2016*  
[Quarterly Report \(10-Q\)](#)